Seattle Genetics' stock falls despite panel recommendation

Seattle Genetics' stock price fell to $19.17 in pre-market trading despite yesterday's expert panel recommendation accelerated approval of the company's drug, brentuximab vedotin (Adcetris). Investors are apparently concerned that the FDA may ask for more data about the drug's benefits given the fact that the developer only conducted two small trials for the blood cancer drug. The developer's stock dropped to $18.81 after the market opened. Story

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.